Xcout IntelAxsome Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Axsome Therapeutics among biopharmaceuticals companies — ranked by similarity to what Axsome Therapeutics actually does, not by market-cap band.
Subscribe to see Axsome Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Axsome Therapeutics
Axsome Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative treatments for central nervous system (CNS) disorders, primarily focusing on the United States market. Its pipeline includes AXS-05, a therapeutic candidate for major depressive disorder and treatment-resistant depression, which is also currently in Phase III clinical trials for Alzheimer's disease agitation and has completed Phase II studies for smoking cessation. The company is also advancing AXS-07, an experimental, rapidly absorbed, oral medication with a multi-mechanistic profile, which has successfully concluded two Phase III trials for the acute treatment of migraine. Another key asset is AXS-12, a selective and potent norepinephrine reuptake inhibitor, presently in Phase III development for narcolepsy. Furthermore, AXS-14, an investigational oral medicine, is undergoing Phase III trials for fibromyalgia. Axsome Therapeutics maintains a research collaboration with Duke University to further evaluate AXS-05 for smoking cessation. The company was founded in 2012 and is headquartered in New York, New York.
Axsome Therapeutics at a glance
Axsome Therapeutics is a biopharmaceuticals company headquartered in New York City, United States. It is publicly listed (0HKF) with a market capitalisation of $11.5B. Xcout tracks 12 named people at Axsome Therapeutics, including Mark L. Jacobson (Chief Operating Officer). Xcout recorded 173 job postings from Axsome Therapeutics in the last 90 days, naming tools such as Salesforce, Power BI, Tableau.
Axsome Therapeutics leadership
- Mark L. JacobsonChief Operating Officer
- Nick PizzieChief Financial Officer
- Ari MaizelChief Commercial Officer
- Herriot TabuteauFounder, Chairman, Chief Executive Officer & President
- Darren OplandDirector of Corporate Communications
- Hunter MurdockGeneral Counsel & Secretary
6 more named people on record for Axsome Therapeutics, with roles, board committees and tenure — see the full roster →
Axsome Therapeutics funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $52M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Axsome Therapeutics
Xcout recorded 173 job postings from Axsome Therapeutics in the last 90 days, from a hiring record Xcout has kept since May 2026.
Tools named in Axsome Therapeutics's job postings
The weekly hiring trend, the roles and locations behind it — see Axsome Therapeutics's hiring signals →
Top 12 Axsome Therapeutics competitors
Ranked by semantic similarity — how close each company is to Axsome Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biopharmaceuticals company
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder. Beyond its current commercial use, BXCL501 is also undergoing further clinical investigation. Studies are underway to assess its efficacy for agitation in individuals with Alzheimer's disease, as an add-on therapy for major depressive disorder, and for use in community settings to address agitation linked to bipolar disorders and schizophrenia. Furthermore, BioXcel is advancing BXCL502, a candidate therapy targeting chronic agitation prevalent in dementia patients. Another key pipeline asset is BXCL701, an orally administered systemic innate immunity activator currently under investigation. This compound shows promise for treating aggressive prostate cancer and advanced solid tumors that have either become resistant to checkpoint inhibitors or have not yet received such treatment. Established in 2017, the company maintains its headquarters in New Haven, Connecticut.
Similar biopharmaceuticals company
Biohaven is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments across key therapeutic areas. Headquartered with operations in New Haven, Connecticut, the company advances innovative neuroscience and specialty therapeutics.
Similar biopharmaceuticals company
Nexalis Health, Inc. (operating as Nexalis Therapeutics) is a clinical-stage biopharmaceutical company that develops oral and inhaled therapies for pain management and mental health conditions. Its pipeline includes three drug candidates addressing treatment-resistant depression, breakthrough cancer pain, and panic disorder.
Drug Discovery
Tortugas Neuroscience is a drug discovery and biopharmaceutical company headquartered in Framingham, Massachusetts. The company focuses on advancing innovative neuroscience therapeutics.
Biopharma
Engrail Therapeutics, Inc. is a clinical-stage neurosciences and pharmaceutical company established in 2019 and headquartered in San Diego, California. The firm focuses on developing novel treatments such as its planned ENX-104 clinical program.
Similar biopharmaceuticals company
Cerevel Therapeutics was a U.S. biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders, including schizophrenia, Parkinson’s disease, and Alzheimer’s disease. Its therapies were intended to serve patients with serious central nervous system conditions and the healthcare providers treating them.
Drug Discovery
Object Pharma is a privately held biopharmaceutical company headquartered in Aliso Viejo, California, founded in 2018. The company is dedicated to developing novel treatments for mental health disorders and manufactures botulinum toxin products for accredited research use.
Similar biopharmaceuticals company
AgeneBio, Inc. is a development-stage CNS biopharmaceutical company located in Baltimore, Maryland, focused on discovering and developing innovative therapeutics to preserve and restore brain function.
Similar biopharmaceuticals company
1ST Biotherapeutics is a South Korean biopharmaceutical company focused on discovering and developing treatments for neurodegenerative and other central nervous system diseases. Its work is aimed at patients with disorders such as Alzheimer’s disease and related conditions.
Drug Discovery
Cognito Therapeutics Ltd. is a clinical-stage company headquartered in Cambridge, Massachusetts, that has conducted multiple clinical studies for its therapeutic products.
Biopharmaceutical
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Drug Discovery
Metsera, Inc. is a clinical-stage biopharmaceutical company traded on the NASDAQ under the symbol MTSR, with its headquarters located in New York, New York, focusing on next-generation obesity and metabolic portfolios.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Axsome Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Axsome Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →